Pharmaceutical Composition for Use in the Treatment of a Neurodegenerative Disease

Abstract

The present invention refers to a pharmaceutical composition for use in the treatment of a neurodegenerative disease.

1 : A method for treating stroke in a patient in need thereof, comprising
 administering to said patient a therapeutically effective amount of a pharmaceutical composition comprising desPro 36 Exendin-4(1-39)-Lys 6 -NH 2  (“lixisenatide”) or a pharmaceutically acceptable salt thereof, and   optionally a pharmaceutically acceptable carrier, adjuvant, auxiliary substance or a combination thereof.   
     
     
         2 : The method according to  claim 1 , wherein the lixisenatide or pharmaceutically acceptable salt thereof is administered parenterally. 
     
     
         3 : The method according to  claim 1 , wherein the lixisenatide or pharmaceutically acceptable salt thereof is administered in a daily dose selected from the range of 10 μg to 20 μg. 
     
     
         4 : The method according to  claim 1 , wherein the stroke is associated with death of cortical or striatal neurons or neuronal loss caused by ischemia. 
     
     
         5 : The method according to  claim 4 , wherein the composition attenuates neuronal loss caused by ischemia. 
     
     
         6 : The method according to  claim 1 , wherein the composition elicits a reduction in brain damage. 
     
     
         7 : The method according to  claim 1 , wherein the composition elicits a disease-modifying response.